Study of Epcoritamab in Relapsed and Refractory Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2030

Conditions
Primary CNS Lymphoma (PCNSL)
Interventions
DRUG

Epcoritamab

Epcoritamab Investigational Medicinal Product (IMP): Epcoritamab will be used during induction phase and Maintenance phase.

Trial Locations (13)

Unknown

INSTITUT BERGONIE - Service d'Oncologie Médicale, Bordeaux

INSTITUT D'HEMATOLOGIE DE BASSE NORMANDIE - Service Hématologie, Caen

CHU ESTAING - Service Thérapie Cellulaire et Hématologie Clinique, Clermont-Ferrand

CHU DE LILLE - HOPITAL CLAUDE HURIEZ - Service des Maladies du Sang, Lille

CHR DE MARSEILLE - CHU TIMONE - Service de Neuro-Oncologie, Marseille

CHRU DE NANCY - HOPITAL CENTRAL - Service de Neurologie, Nancy

GHU PITIE-SALPETRIERE - CHARLES FOIX - Service Neurologie, Paris

HOPITAL DE LA PITIE SALPETRIERE - Service Hématologie Clinique, Paris

CHU LYON-SUD - Hématologie Clinique, Pierre-Bénite

CHU PONTCHAILLOU - Hématologie Clinique, Rennes

INSTITUT CURIE - SITE SAINT-CLOUD - Service Hématologie, Saint-Cloud

IUCT ONCOPOLE - Service Hématologie, Toulouse

CHU BRETONNEAU - Service Cancérologie - Hématologie et Thérapie Cellulaire, Tours

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

The Lymphoma Academic Research Organisation

OTHER